LOS ANGELES, Sept. 30, 2009 (GLOBE NEWSWIRE) -- Cardo Medical (OTCBB:CDOM), a company engaged in the development of orthopedic medical devices, announces the introduction and first successful implantation of the Align 360(TM) Total Knee system. The initial release will follow with a commercial release to an expanded surgeon network over the upcoming quarters. Cardo Medical recently commercialized its Total Knee system as an adjunct to its Align 360 Knee platform which consists of its clinically proven Uni-Compartmental Knee system and its Patello-Femoral Knee system. All three "A La Carte Knee Remodeling(TM)" systems within the Align 360 Knee platform are designed to be highly bone conserving and feature a unique modular approach and common instrumentation system with a revolutionary concept designed to deliver simplified, reproducible surgical outcomes.
Dr. Andrew Brooks, Chairman and Chief Executive Officer of Cardo Medical stated, "Cardo has attained another important company milestone, with the first implantation of our bone-conserving, high performance total knee implant system. We are very pleased with the component design, simplicity and elegance of our instrumentation and look forward to introducing this state of the art knee remodeling system to orthopedic surgeons across the country." Michael Kvitnitsky, President and Chief Operating Officer of Cardo Medical added, "Cardo is investing aggressively in advanced technologies that will benefit patients. Introduction of the Align 360 Total Knee system reflects the ongoing efforts at Cardo to address the unmet clinical needs with unique product designs."
About Cardo Medical, Inc.
Cardo Medical (OTCBB:CDOM) develops reconstructive orthopedic and spinal surgery products through advanced engineering and focuses on product development, marketing and distribution within the U.S. market. Cardo Medical's superior engineering talent closely collaborates with leading surgeons around the country to create products that reduce or eliminate joint pain and allow patients to achieve more active lives. The company's cutting edge products are specifically developed with patients, surgeons and OR staff in mind and are designed to reduce operative time, enhance surgical technique, shorten hospital stays, reduce recovery time and improve outcomes. Cardo Medical's product portfolio includes devices for knee, hip, spinal fusion and motion preservation arthroplasty and replacement, many of which have already received FDA clearance. Cardo Medical has a robust and innovative product pipeline pending both USPTO and FDA submission and clearance.
Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website at www.cardomedical.com for more information on the Align 360 Total Knee System in addition to our portfolio of other Reconstructive and Spinal Implant systems.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.